Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.

Abstract: The present invention is directed to the use of (3-Amino-2-fluoropropyl)phosphinic acid or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of non-erosive reflux disease (NERD).

Abstract: Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.

Abstract: In one embodiment, a computer-implemented method of managing a computer network includes installing an agent in each of a plurality of network nodes in the network. The agent may be configured to identify one or more types of network resources attached to a particular node with which the agent is associated. One or more roles may be assigned to or by the agent based, at least in part, upon the one or more types of network resources identified by the agent. Functions associated with the identified roles may be executed. Monitoring the status of each agent may also be carried out. In another embodiment, a network management system includes an agent executing within an associated network node of the network. The agent may be configured to operate so as to identify one or more types of resources attached to the network node. The agent may be assigned one or more roles based, at least in part, on an inference based upon the one or more types of attached resources identified by the agent.

Abstract: In some aspects of the invention, a method for determining access to data stored within one or more databases is described. The method includes the aspects of receiving a user request from a user at an inference engine for access to the data, wherein the inference engine is in communication with a rules database, including one or more rules governing access rights to the data. Moreover, the method includes the aspects of creating a user credential based on the application of one or more of the rules to a identity information related to the user. Further, the method includes the aspects of comparing the created user credential and the user request at the one or more databases to determine whether the user meets the access rights for retrieving the data. Furthermore, the method includes aspects of determining an answer as to whether the access of the data is permitted or denied.

Abstract: A system and method for processing an electronic query that includes defining a set of rules accessible to an inference engine and wherein the set of rules are configured for (a) parsing the query into one or more subsequent-queries; and (b) determining whether additional information is necessary to answer each subsequent-query and, if so, (i) accessing a registry containing descriptions of one or more data resources, (ii) analyzing the descriptions of the one or more data resources to locate information responsive to the subsequent-query; and then the system and method could apply the set of rules to the information, aggregate all of the information responsive to the query, and supply an answer to the query that is compliant with the set of rules.

Abstract: The administration of cannabinoid receptor agonists for inhibition of transient lower esophageal sphincter relaxations, gastroesophageal reflux disease and regurgitation is disclosed.

Abstract: The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough.

Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of irritable bowel syndrome (IBS).

Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.

Abstract: Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts; solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.

Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment or prevention of cough.

Abstract: The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough.

Abstract: The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough.

Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspects of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastro, esophageal reflux disease, as well as for the treatment of regurgitation and asthma.

Abstract: Novel compounds of formula (I) wherein R1 represents hydrogen; R2 represents hydroxy, fluoro, or an oxo group; R3 represents hydrogen; R4 represents hydrogen; and pharmaceutically acceptable salts, solvates, and the stereoisomers thereof, with the exception of the racemate of (3-amino-2-hydroxypropyl)sulphinic acid. The compounds are useful in therapy, especially for the treatment of reflux disease.

Abstract: The present invention relates to the use of cannabinoid receptor agonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of cannabinoid receptor agonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation such as regurgitation in infants, lung disease, chronic laryngitis and asthma.

Abstract: Novel compounds of formula (I) wherein R1 represents hydrogen; R2 represents hydroxy, fluoro or an oxo group; R3 represents hydrogen; R4 represents hydrogen; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, with the exception of the racemate of (3-amino-2-hydroxypropyl)sulphinic acid. The compounds are useful in therapy, especially for the treatment of reflux disease. The invention is also related to processes for their preparation, intermediates of said process and pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.

Abstract: The present invention relates to the use of GABAB receptor agonists for the inhibition of transient lower esophageal sphincter relaxations, and for the treatment of gastro-esophageal reflux disease.

Abstract: The present invention relates to the use of GABA.sub.B receptor agonists for the inhibition of transient lower esophageal sphincter relaxations, and for the treatment of gastro-esophageal reflux disease.